Remeron is the brand name for mirtazapine, a prescription antidepressant used primarily to treat major depressive disorder in adults. It belongs to a class of antidepressants known as noradrenergic and specific serotonergic antidepressants. Mirtazapine works by influencing noradrenergic and serotonergic activity in the brain. It is available as conventional oral tablets and as an orally disintegrating formulation called RemeronSolTab. Current FDA labeling identifies Remeron and RemeronSolTab as treatments for major depressive disorder in adults.

Important Warnings while taking Remeron

Remeron carries a boxed warning regarding suicidal thoughts and behaviors associated with antidepressant use. Antidepressants may increase the risk of suicidal thinking or behavior in children, adolescents, and young adults, particularly during the initial stages of treatment or when the dose is changed. Patients and caregivers should monitor for new or worsening depression, unusual behavioral changes, agitation, or suicidal thoughts and promptly communicate concerning changes to a healthcare professional. Remeron is not approved for paediatric patients.

Mirtazapine should not be taken with or within 14 days of treatment with a monoamine oxidase inhibitor because of the potential for serious reactions. A 14-day interval is also required after stopping mirtazapine before beginning an MAOI. Combining serotonergic medicines can also increase the risk of serotonin syndrome, which may involve agitation, confusion, sweating, fever, rapid heart rate, muscle rigidity, or changes in blood pressure.

Remeron may cause sleepiness and impaired alertness, particularly during the early stages of treatment. Alcohol and other medicines that cause sedation can increase this effect. Patients should be careful when driving or operating machinery until they understand how the medicine affects them.

Mirtazapine can also increase appetite and body weight. Changes in cholesterol and triglyceride levels have been reported, so healthcare professionals may consider monitoring weight and metabolic parameters when appropriate.

Rarely, mirtazapine can cause neutropenia or agranulocytosis, conditions involving abnormally low white blood cell counts. Fever, sore throat, mouth ulcers, or other signs of infection should be reported promptly, particularly if they occur during treatment.

Things to consider before Remeron consumption

Before starting Remeron, patients should discuss the following conditions and medicines with their healthcare professional:

• Depression and suicidal thoughts
• Bipolar disorder
• Liver or kidney disease
• Seizure disorders
• Low blood pressure
• Low white blood cell count
• Heart problems
• Glaucoma
• Pregnancy and breastfeeding
• Other medicines interact with mirtazapine.
• Allergy

They are used for pain relive, but it is advised to inform the healthcare professional if patients are allergic to the medicine, have history related to disorders related to brains, heart problems, kidney or other related diseases. Informing the doctor is important if the patient is pregnant and breastfeeding as it may harm the foetus.

Application/Consumption

Remeron is taken orally, generally once daily and preferably in the evening before sleep because it can cause drowsiness. The medicine can be taken with or without food. Patients should follow the prescribed dose and should not increase, decrease, or discontinue treatment without consulting their healthcare professional.

RemeronSolTab is an orally disintegrating tablet. It should remain in its blister package until it is ready to be taken. After opening the blister with dry hands, the tablet should be placed on the tongue and allowed to dissolve in saliva. It should not be crushed or split.

Patients should avoid excessive alcohol consumption because alcohol can increase the sedating effects of mirtazapine. Because antidepressant treatment may take several weeks to produce its full therapeutic effect, patients should continue treatment as prescribed unless their healthcare professional advises otherwise.

Stopping mirtazapine suddenly may result in discontinuation symptoms. When treatment needs to be stopped, the healthcare professional may gradually reduce the dose rather than stopping it abruptly.

Dosing information

The recommended starting dose of Remeron or RemeronSolTab for adults with major depressive disorder is 15 mg once daily, preferably in the evening before sleep. If the response is inadequate, the dose may be increased up to a maximum of 45 mg per day. 

Patients with significant liver or kidney impairment may require additional consideration because mirtazapine clearance can be reduced. 

Uses

Remeron is used for:

• Major depressive disorder in adults.
• Treatment of depressive symptoms such as persistent low mood, loss of interest, changes in sleep, appetite changes, low energy, and difficulty concentrating when these occur as part of major depressive disorder.
• Maintenance treatment in patients who respond to mirtazapine, with continued treatment periodically reassessed by the healthcare professional.
• Remeron is not approved by the FDA for pediatric use, and its use for conditions other than its approved indication should be determined by a healthcare professional.

Remeron side effects

Common side effects of mirtazapine include sleepiness, increased appetite, weight gain, dizziness, dry mouth, and constipation. Increased appetite and weight gain are particularly relevant because mirtazapine can affect appetite and metabolic parameters. Some patients may also experience fatigue, abnormal dreams, nausea, or headache.

Sedation can be significant, especially during the first part of treatment. Patients should avoid driving or operating machinery until they know how the medicine affects their alertness. Combining mirtazapine with alcohol, opioids, benzodiazepines, sleep medicines, or other sedating substances can further increase central nervous system depression.

Mirtazapine may also cause orthostatic hypotension, meaning a drop in blood pressure when moving from sitting or lying down to standing. This can result in dizziness or, less commonly, fainting. Patients should stand slowly and discuss persistent dizziness with their healthcare professional.

Rare but serious adverse effects include serotonin syndrome, severe allergic reactions, mania or hypomania, seizures, and significant reductions in white blood cells. Symptoms such as fever, sore throat, mouth ulcers, or other signs of infection can be important because severe neutropenia and agranulocytosis have been reported with mirtazapine.

Mirtazapine may affect cholesterol and triglyceride levels, so monitoring may be appropriate for patients with existing metabolic risk factors. Significant or unexplained weight changes should also be discussed with a healthcare professional.

Drug interactions are particularly important with MAOIs. Remeron must not be used with an MAOI or within the required 14-day interval between these treatments. Strong CYP3A4 inhibitors may increase mirtazapine exposure, while strong CYP3A4 inducers such as carbamazepine, phenytoin, or rifampin may reduce exposure and potentially require dosage adjustment.

Patients should seek urgent medical attention for severe allergic symptoms, severe confusion or agitation with fever and muscle rigidity, seizures, fainting, or symptoms suggesting a serious infection.

Key Insights:

While the brand-name Remeron has been available as a generic for over two decades, the FDA continues to approve new generic manufacturing lines. The newest generic mirtazapine tablet market launches include:

• Novitium Pharma launched generic 15 mg and 30 mg mirtazapine tablets. 
• Annora Pharma generic released 15mg and 30mg formulations. 
• Micro Labs generic rolled out additional generic availability of 15 mg and 30 mg. 
• https://www.drugs.com/availability/generic-remeron.html